Roche licenses Simcere’s B-cell-targeting tri-specific for $1.53bn - Pharmaceutical Technology

The antibody is designed to provide broad coverage across B-cell mediated diseases and might have autoimmune therapeutic potential. The antibody is designed to provide broad coverage across B-cell mediated diseases and might have autoimmune therapeutic potential. While only a preclinical asset currently, the licensing fee paid by Roche reflects the potential wide use cases for SIM0660. Credit: Michael Vi/Shutterstock.com. Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends. With a free Pharmaceutical Technology profile, you can: The leading site for news and procurement in…

Source: Pharmaceutical Technology